USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOSURFACES
Address:
200 Homer Avenue, Unit 1P
ASHLAND, MA
Phone:
N/A
URL:
N/A
EIN:
126250296
DUNS:
131658739
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $811,077.00 3
SBIR Phase II $1,738,074.00 2
STTR Phase I $460,528.00 4
STTR Phase II $1,493,567.00 2

Award List:

A Nanofibrous Biocomposite Small-Diameter Graft

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is no small-diameter (< 5mm internal diameter) vascular prosthesis clinically available that is capable of emulating the biological and physical properties of the normal arterial wall. The goal of this two-year phase I project, which unites a diverse… More

Development of Infection-Resistant Suture Materials

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF RHODE ISLAND
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Infection remains as one of the major complications associated with utilizing biomaterials. Surgical site infections account for approximately 14-16% of the 2.4-million nosocomial infections in the United States, with these infections resulting in increased… More

A Nanofibrous Biocomposite Small-Diameter Graft

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is no small-diameter (< 5mm internal diameter) vascular prosthesis approved for clinical use in small vessel reconstruction. Current prostheses are not capable of emulating the biological and physical properties of the normal arterial wall, resulting in… More

Development of Infection-Resistant Suture Materials

Award Year / Program / Phase:
2006 / STTR / Phase II
Award Amount:
$744,617.00
Agency:
HHS
Principal Investigator:
Research Institution:
BETH ISRAEL DEACONESS MEDICAL CENTER
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Infection remains as one of the major complications associated with utilizing biomaterials. Surgical site infections account for approximately 14-16% of the 2.4-million nosocomial infections in the United States, with these infections resulting in increased… More

STTR Phase I: Localized Gene Delivery from Implantable Arterial Devices

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$150,000.00
Agency:
NSF
Principal Investigator:
Research Institution:
Beth Israel Deacness Medical Center
RI Contact:
Christine A. Ferran
Abstract:
This Small Business Technology Transfer (STTR) Phase I research project aims to develop a fibrous material for the embedment and gradual release of appropriate genetic material, including small interfering RNA (siRNA), and viral vectors carrying genes for anti-inflammatory molecules, from coronary… More

A Bioactive Prosthetic Vascular Graft

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are comprised of either polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Medium (6-8mm) and small (l t5mm) internal diameter (I.D.) prosthetic… More

An Endothelial Progenitor Cell-Specific Nanofibrous Vascular Graft

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$499,998.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are comprised of either polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Medium (6-8mm) internal dia meter (I.D.) prosthetic arterial grafts… More

A Nanofibrous Bioactive Prosthetic Sewing Cuff

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$110,528.00
Agency:
HHS
Principal Investigator:
Research Institution:
BETH ISRAEL DEACONESS MEDICAL CENTER
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative disease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting on cardiac output. An estimated 50,000 prosthetic valves are… More

A Nanofibrous Bioactive Hemodialysis Access Graft

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$111,079.00
Agency:
HHS
Principal Investigator:
Saif G. Pathan
Abstract:
DESCRIPTION (provided by applicant): Current gold standards for hemodialysis access, radial cephalic vein fistulas and autogenous saphenous veins, have significant problems associated with their use. Many patients do not have a healthy vein to spare due to disease progression or prior/future use… More

A Bioactive Prosthetic Vascular Graft

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$748,950.00
Agency:
HHS
Principal Investigator:
Matthew D. Phaneuf – 508-881-8860
Research Institution:
BETH ISRAEL DEACONESS MEDICAL CENTER
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are primarily comprised of polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Unfortunately, these grafts continue to have high failure rates due… More

A Nanofibrous Bioactive Hemodialysis Access Graft

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$988,074.00
Agency:
HHS
Principal Investigator:
Saif G. Pathan – 508-881-8860
Abstract:
DESCRIPTION (provided by applicant): Current gold standards for hemodialysis access to treat End-Stage Renal Disease (ESRD), radial cephalic vein fistulas and autogenous saphenous veins, have significant problems associated with their use. The issues rangefrom unavailability of a healthy vein the… More